



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

10 May 2021
EMA/CAT/224917/2021
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 14-16 April 2021

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

Disclaimers

Some of the information contained in these minutes are considered commercially confidential or sensitive and therefore not disclosed. Regarding intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	6
2.3.1.	lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - EMEA/H/C/004731	6
2.3.2.	elivaldogene autotemcel - Orphan - EMEA/H/C/003690	6
2.3.3.	eladocagene exuparvovec - Orphan - EMEA/H/C/005352	6
2.4.	Day 120 list of questions	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	7
2.6.1.	autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - EMEA/H/C/003693	7
2.7.	New applications	7
2.8.	Withdrawal of initial marketing authorisation application	7
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	7
2.10.	GMP and GCP inspections requests.....	7
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0021/G	7
2.11.2.	Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0022.....	7
2.11.3.	Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102/II/0001.....	8
2.11.4.	Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0028.....	8
2.11.5.	Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0035.....	8
2.11.6.	Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/II/0022.....	9
2.12.	Extension applications.....	9
2.13.	Other Post-Authorisation Activities	9
2.13.1.	Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.4.....	9

2.13.2.	Committees discussion and outcome on milestones and performance indicators for the deadline for improvement for imposed PASS using the European Society for Blood and Marrow Transplantation (EBMT) as data source.....	9
---------	---	---

3. Certification of ATMPs 9

3.1.	Opinion.....	10
3.2.	Day 60 Evaluation Reports.....	10
3.3.	New Applications.....	10

4. Scientific Recommendation on Classification of ATMPs 10

4.1.	New requests – Appointment of ITF Coordinator.....	10
4.1.1.	<i>Ex-vivo</i> expanded autologous cryopreserved Wharton’s Jelly derived mesenchymal stem cells (CWJ-MSCs).....	10
4.1.2.	Allogeneic corneal endothelial cells in a confluent monolayer adhering to a cornea-shaped sheet of cross-linked collagen	10
4.1.3.	Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype.....	10
4.1.4.	Allogeneic human Wharton’s jelly derived mesenchymal stem cells.....	10
4.2.	Day 30 ATMP scientific recommendation	11
4.2.1.	Allogeneic, expanded, engineered E4ORF1+ human umbilical cord endothelial (CD31+) cells.....	11
4.2.2.	Oncolytic adenovirus.....	11
4.2.3.	Autologous antigen presenting cells loaded with SARS-CoV-2 antigen	11
4.2.4.	Autologous mesenchymal stem cells combined with a matrix pre-loaded with BMP2.....	11
4.2.5.	DNA plasmid encoding several neoepitopes from the tumour of a patient, a live wild-type modified vaccinia strain Ankara (MVA) and a monoclonal antibody against Cytotoxic T-lymphocyte associated protein 4 (CTLA4)	11
4.2.6.	Autologous cultured chondrocytes.....	12
4.2.7.	Recombinant adeno-associated virus encoding for the human α -sarcoglycan-protein.....	12
4.3.	Day 60 revised scientific recommendation (following list of questions)	12
4.4.	Finalisation of procedure	12
4.4.1.	Autologous antigen specific Cytotoxic T Lymphocytes.....	12
4.4.2.	Autologous dendritic cells activated against tumour peptides	12
4.4.3.	Autologous M1-polarized macrophages.....	13
4.4.4.	Autologous Cytotoxic Natural Killer (NK) cells.....	13
4.4.5.	Autologous plasma cells producing monoclonal antibodies against specific tumor antigen, for treatment of cancer patients	13
4.5.	Follow-up and guidance.....	13

5. Scientific Advice 13

5.1.	New requests – appointment of CAT Rapporteurs	13
5.1.1.	Ongoing scientific advice procedures – Appointment of CAT Peer-Reviewers	13
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	13
5.2.	CAT discussion.....	14

5.3.	Finalisation of SA procedures	14
-------------	--	-----------

6.	Pre-Authorisation Activities	14
-----------	-------------------------------------	-----------

6.1.	Paediatric investigation plans.....	14
6.2.	ITF briefing meetings in the field of ATMPs	14
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	14
6.3.1.	Month 0 - Start of the procedure	14
6.3.2.	Month 1 – Discussion of eligibility	14
6.3.3.	Month 2 – Recommendation of eligibility.....	14
6.3.4.	Ongoing support.....	14

7.	Organisational, regulatory and methodological matters	15
-----------	--	-----------

7.1.	Mandate and organisation of the CAT	15
7.1.1.	CAT membership	15
7.1.2.	Strategic Review & Learning meeting (SRLM) under the Portuguese presidency of the European Union - Lisbon, Portugal	15
7.1.3.	Overview of WebEx - new virtual meetings platform	15
7.2.	Coordination with EMA Scientific Committees.....	15
7.2.1.	CHMP learnings that impact CAT decisions	15
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	16
7.3.1.	QWP/BWP Guideline on quality documentation for medicinal products when used in combination with a medical device.....	16
7.3.2.	Scientific Advisory Group (SAG) – renomination of the inter-committee SAG oncology (SAG-O) – request for nominations.....	16
7.4.	Cooperation within the EU regulatory network.....	16
7.4.1.	Revision of the EU legislation on blood, tissues and cells (BTC).....	16
7.4.2.	Data standards strategy survey and virtual workshop to take place on 18 May 2021	16
7.4.3.	Pharmaceutical strategy for Europe.....	17
7.4.4.	Verification of conditions of transport in cases foreseen under Section 11.17 of GMP for ATMPs	17
7.5.	Cooperation with international regulators.....	17
7.6.	CAT work plan	17
7.7.	Planning and reporting	17
7.8.	Others	17

8.	Any other business	17
-----------	---------------------------	-----------

9.	Explanatory notes	18
-----------	--------------------------	-----------

10.	List of participants	22
------------	-----------------------------	-----------

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 14-16 April 2021 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 17-19 March 2021 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - EMEA/H/C/004731

Bristol-Myers Squibb Pharma EEIG; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: Day 180 list of outstanding issues

Action: for adoption

List of Questions adopted on 06.11.2020.

The Rapporteurs presented the outcome of the assessment of the responses to the list of questions.

CAT adopted the list of outstanding issues and the review timetable.

2.3.2. Elivaldogene autotemcel - Orphan - EMEA/H/C/003690

Bluebird bio (Netherlands) B.V; treatment of ABCD1 genetic mutation and cerebral adrenoleukodystrophy

Scope: List of outstanding issues.

Action: for adoption

List of Questions adopted on 22.01.2021.

The Rapporteurs presented the outcome of the assessment of the responses to the list of questions. The outstanding issues were discussed. CAT adopted the list of outstanding issues and the review timetable.

2.3.3. Eladocagene exuparvovec - Orphan - EMEA/H/C/005352

PTC Therapeutics International Limited; treatment of aromatic L-amino acidcarboxylase (AADC) deficiency

Scope: Day 180 list of outstanding issues

Action: for adoption

List of Questions adopted on 20.05.2020.

The Rapporteurs presented to outcome of the assessment of the responses to the list of questions. The outstanding issues were discussed.

CAT adopted the list of outstanding issues and the review timetable.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: Request for clock stop extension

Action: for adoption

CAT agreed with a clock stop extension. The review timetable was adopted.

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0021/G

CO.DON AG

Rapporteur: Lisbeth Barkholt

Scope: Quality

Action: for adoption

Request for Supplementary Information adopted on 19.02.2021.

The opinion was adopted.

2.11.2. Spherox - spheroids of human autologous matrix-associated chondrocytes - EMEA/H/C/002736/II/0022

CO.DON AG

Rapporteur: Lisbeth Barkholt

Scope: Clinical

Update of section 5.1 of the SmPC with the final results of study 'cod 16 HS 13', a 60-month follow up data assessing long-term efficacy and safety of Spherox.
Annex II has also been updated to reflect the completion of the study.

Action: for adoption

Request for Supplementary Information adopted on 19.03.2021.

The opinion was adopted.

2.11.3. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102/II/0001

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality.

Action: for adoption

The opinion was adopted.

2.11.4. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0028

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus; PRAC Rapporteur: Anette Kirstine Stark

Scope: Clinical

To update SmPC sections; 4.4 on CRS grading and neurologic adverse reactions; 4.8 on safety profile summary; 5.1 on follow up analysis; to update the safety information based on updates from study KTE-C19-101, entitled "A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)", the pivotal study for Yescarta. The updates include the Phase 2 safety management ZUMA-1 Cohort 4, which was intended to assess the impact of earlier interventions (tocilizumab and/or corticosteroids, in addition to prophylactic levetiracetam) on the rate and severity of CRS and neurologic events; and data from a 36-month analysis from ZUMA-1 Cohorts 1 and 2.

The updated RMP version 3.1 has also been submitted.

Action: for adoption

Request for Supplementary Information adopted on 19.02.2021, 09.10.2020.

The Rapporteur presented the outcome of the assessment. The opinion was adopted.

2.11.5. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0035

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality.

Action: for adoption

The opinion was adopted.

2.11.6. Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/II/0022

Bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, CHMP Coordinator: Paula van Hennik

Scope: Quality. Request for RSI

Action: for adoption

The opinion was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.4

Novartis Europharm Limited

Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang

Scope: PhV

Study CCTL019H2301:

In order to further characterise the long-term efficacy and safety of Kymriah in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL) the applicant should submit the results of study CCTL019H2301 - open-label, Phase III study of Kymriah versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin

Action: for adoption

The assessment report was adopted.

2.13.2. Committees discussion and outcome on milestones and performance indicators for the deadline for improvement for imposed PASS using the European Society for Blood and Marrow Transplantation (EBMT) as data source

Scope: debrief to the CAT on the communication of the March Outcome to MAH and EBMT, and notes from the teleconference with EBMT that took place on 22 March 2121

Action: for information

CAT was informed of the letter that was received from EBMT and the subsequent teleconference that took place on 22 March. EBMT confirmed their commitment to improve the patient-based reporting.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of ITF Coordinator

4.1.1. *Ex-vivo* expanded autologous cryopreserved Wharton's Jelly derived mesenchymal stem cells (CWJ-MSCs)

Intended for the treatment of Bronchopulmonary Dysplasia (BPD) for preterm infants

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.1.2. Allogeneic corneal endothelial cells in a confluent monolayer adhering to a cornea-shaped sheet of cross-linked collagen

Intended for the treatment of corneal dysfunction

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.1.3. Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype

Intended for the treatment of acute myeloid leukaemia

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.1.4. Allogeneic human Wharton's jelly derived mesenchymal stem cells

Intended for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis after COVID-19

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT Coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic, expanded, engineered E4ORF1+ human umbilical cord endothelial (CD31+) cells

Intended to treat organ vascular niche injuries caused by myeloablative, non-central nervous system penetrating high-dose chemotherapy (HDT) to prevent the development of severe regimen-related toxicities (SRRT) in patients diagnosed with aggressive systemic lymphoma

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT considered that additional information should be provided by the applicant before concluding on the classification

The procedural clock will be stopped awaiting responses from the applicant.

4.2.2. Oncolytic adenovirus

Intended for the treatment of histologically and radiologically confirmed progressive neuroendocrine neoplasm (NEN) of gastrointestinal, pancreatic or bronchial origin with multiple liver metastases (liver-dominant disease)

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.2.3. Autologous antigen presenting cells loaded with SARS-CoV-2 antigen

Vaccine against SARS-CoV-2 Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.2.4. Autologous mesenchymal stem cells combined with a matrix pre-loaded with BMP2

Intended to treat femoral osteochondral lesion (grade III to IV)

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.2.5. DNA plasmid encoding several neoepitopes from the tumour of a patient, a live wild-type modified vaccinia strain Ankara (MVA) and a monoclonal antibody against Cytotoxic T-lymphocyte associated protein 4 (CTLA4)

Intended for the treatment of cancer

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.2.6. Autologous cultured chondrocytes

Intended for the treatment of filling of cartilage defects

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.2.7. Recombinant adeno-associated virus encoding for the human α -sarcoglycan-protein

Intended for the treatment of patients with a confirmed diagnosis of Limb-Girdle muscular dystrophy Type 2D/R3 (LGMD2D/R3)

Scope: ATMP Scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 30 April 2021.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous antigen specific Cytotoxic T Lymphocytes

Intended for the treatment of cancer patients that are over expressing the specific antigen

Scope: minor comments received by the European Commission. ATMP scientific recommendation

Action: for information

The information was noted. The classification report will be sent to the applicant.

4.4.2. Autologous dendritic cells activated against tumour peptides

Intended for the treatment of cancer patients; *in vivo* immune stimulation against specific cancer overexpressing the tumour antigen

Scope: minor comments received by the European Commission. ATMP scientific recommendation

Action: for information

The information was noted. The classification report will be sent to the applicant.

4.4.3. Autologous M1-polarized macrophages

Intended for the treatment of cancer patients

Scope: minor comments received by the European Commission. ATMP scientific recommendation

Action: for information

The information was noted. The classification report will be sent to the applicant.

4.4.4. Autologous Cytotoxic Natural Killer (NK) cells

Intended for the treatment of cancer patients

Scope: minor comments received by the European Commission. ATMP scientific recommendation

Action: for information

The information was noted. The classification report will be sent to the applicant.

4.4.5. Autologous plasma cells producing monoclonal antibodies against specific tumor antigen, for treatment of cancer patients

Intended for the treatment of cancer patients

Scope: minor comments received by the European Commission. ATMP scientific recommendation

Action: for information

The information was noted. The classification report will be sent to the applicant.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures – Appointment of CAT Peer-Reviewers

Timetable:

-Start of the procedure at SAWP:	06-09.04.2021
-Appointment of CAT Peer-reviewers:	16.04.2021
-SAWP first reports:	26.04.2021
-CAT Peer-Reviewer's comments:	30.04.2021
-Discussion at SAWP:	03-06.05.2021
-Discussion at CAT and feedback to SAWP:	12.05.2021

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

-Start of procedure at SAWP:	03-06.05.2021
-Appointment of CAT Peer-Reviewers:	12.05.2021
-SAWP first reports:	31.05.2021
-CAT Peer-Reviewer's comments:	04.06.2021
-Discussion at SAWP:	07-10.06.2021
-Discussions at CAT and feedback to SAWP:	18.06.2021

5.2. CAT discussion

5.3. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	09.04.2021
SAWP recommendation:	06.05.2021
CAT recommendation:	12.05.2021
CHMP adoption of report and final recommendation:	20.05.2021

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Italy – Barbara Bonamassa – membership mandate (alternate) started on 20 March 2021
Italy – Giulio Pompilio – membership mandate (alternate) ended on 19 March 2021

Action: for information

The CAT chair welcomed the new alternate member for Italy and thanked the departing alternate member Giulio Pompilio for his contributions to the CAT.

7.1.2. Strategic Review & Learning meeting (SRLM) under the Portuguese presidency of the European Union - Lisbon, Portugal

CAT: Bruno Sepodes, Maria-Isabel Vieira

Scope: draft agenda of the joint CAT-CHMP meeting that is scheduled to take place at the SRLM on 27th May 2021

Action: for discussion

The agenda of the CAT-CHMP meeting was presented and agreed.

7.1.3. Overview of WebEx - new virtual meetings platform

Scope: training and dates of WebEx for CAT

Action: for information

The CAT Webex roll-out was presented. CAT members were encouraged to join one of the dry-run trainings and also the mock-up meeting that will take place. Invitations will be sent around.

7.2. Coordination with EMA Scientific Committees

7.2.1. CHMP learnings that impact CAT decisions

CAT: Jan Mueller-Berghaus, Romaldas Mačiulaitis, John-Joseph Borg, Bruno Sepodes, Sol Ruíz

Scope: CHMP learnings with relevance to CAT

Action: for information

Romaldas Maciulaitis presented the CHMP learning on the inclusion of safety signals in section 4.8 coming from a phase 1 trial for an extension of the indication. It was agreed that this is also relevant for ATMPs. This CHMP learning will be included in the CAT learnings table.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. QWP/BWP Guideline on quality documentation for medicinal products when used in combination with a medical device

Rapporteur: Nicholas Lee (HPRA-IE)

Action: for adoption

The guideline was adopted.

7.3.2. Scientific Advisory Group (SAG) – renomination of the inter-committee SAG oncology (SAG-O) – request for nominations

Action: for information

The topic was postponed.

7.4. Cooperation within the EU regulatory network

7.4.1. Revision of the EU legislation on blood, tissues and cells (BTC)

CAT-BTC group: Martina Schübler-Lenz, Ilona Reischl, Violaine Closson-Carella, Marcos Timon, Maura O'Donovan, Egbert Flory, Claire Beuneu, Rune Kjeiken, Silke Dorner

Scope: feedback from the teleconferences with the European Commission (EC) on 26 March and 9 April; provide information regarding the dates of the workshops on the context of the impact assessment of the revision of the BTC legislation

Action: for discussion

Detailed feedback was provided from the discussions with EC on the revision of the BTC legislation. The focus of the CAT discussion was on human cell-based products (not blood derived products).

CAT discussed how to make the CAT concerns known to the EC.

Lastly, CAT agreed to participate to following workshop that are hosted by the Commission: Authorising Novel BTC (27 April); Regulating Point-of-Care BTC Processing (bed-side and same surgical procedure) (12 May); Borderlines with Other Regulated Frameworks: Classification Advice and Interplay (09 June). It was noted that some CAT members will participate to these workshops as nominees from their national agencies.

7.4.2. Data standards strategy survey and virtual workshop to take place on 18 May 2021

Scope: contribution to a survey and call for expression of interest for three members of CAT (experts in the field of data standardisation/use, where possible) to actively join the workshop on 18.05.2021.

Action: for information

EMA's Big Data Steering Group has launched an initiative to develop a '*Data Standards Strategy*' that will enable the Network more effectively to leverage data to deliver evidence in support of benefit-risk decision-making on the development, authorisation and use of

medicines. Link to the online survey (*to be opened in Google Chrome*): [LINK](#). The CAT members interested to join the workshop are expected to send their interest. Deadline to contribute to the survey or send the interest for joining the workshop: 23.04.2021.

7.4.3. Pharmaceutical strategy for Europe

Scope: roadmap / inception impact assessment for the revision of the general pharmaceutical legislation

Action: for information

Note: The roadmap is open for feedback until 27 April 2021

https://ec.europa.eu/health/human-use/strategy_en

A presentation of the roadmap was given, and the issues relevant to ATMPs were highlighted: classification and interplay with other legislations; GMO aspects; joint development of medicines and medical devices; new methods of evidence generation such as real world data; addressing unmet medical needs (paediatrics, orphans), and adaptation to cutting-edge products. CAT members can provide comments to the roadmap.

7.4.4. Verification of conditions of transport in cases foreseen under Section 11.17 of GMP for ATMPs

European Commission: Rocío Salvador Roldán

Scope: Question of interpretation of the guidelines of GMP for ATMPs

Action: for information

The question was presented. It was noted that additional information has been requested from the company, but ultimately the company will have to submit a variation prior to implementation.

7.5. Cooperation with international regulators

No items

7.6. CAT work plan

No items

7.7. Planning and reporting

No items

7.8. Others

No items

8. Any other business

No items

Date of next CAT meeting:

10-12/05/2021

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents
RMP: Risk Management Plan
RP: Reflection paper
RSI: Request for supplementary information
SAs: Scientific Advices
SAG-O: Scientific Advisory Group Oncology
SAWP: Scientific Advice Working Party
SR: Summary Report
SWP: Safety Working Party
SME: Small and medium size enterprises
SmPC: Summary of Products Characteristics
TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation

is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 14-16 April 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member (Vice-Chair)	Austria	No interests declared	
Silke Dorner	Alternate	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Petra Sokol	Alternate	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Ivana Haunerova	Member	Czechia	No interests declared	
Tomas Boran	Alternate	Czechia	No interests declared	
Anne Pastoft	Member	Denmark	No interests declared	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Maria Gazouli	Member	Greece	No interests declared	
Angeliki Rompoti	Alternate	Greece	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Niamh Curran	Alternate	Ireland	No restrictions applicable to this meeting	
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No restrictions applicable to this meeting	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No interests declared	
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Guy Berchem	Alternate	Luxembourg	No restrictions applicable to this meeting	
Nancy De Bremaeker	Member	Luxembourg	No interests declared	
John J. Borg	Member (CHMP member)		No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member	Netherlands	No interests declared	
Babs Fabriek	Alternate	Netherlands	No interests declared	
Rune Kjeklen	Member	Norway	No restrictions applicable to this meeting	
Maja Sommerfelt Grønvold	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	
Silviu Istrate	Member	Romania	No interests declared	
Lukas Slovak	Member	Slovakia	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Alexandra Padova	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Sol Ruiz	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Maria Luttgen	Alternate	Sweden	No restrictions applicable to this meeting	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Alessandro Aiuti	Member	Healthcare Professionals' Representative	Restrictions applicable to this meeting	
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Lydie Meheus	Alternate	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	
Olga Kholmanskikh	Expert	BE - Federal Agency for Medicines and Health Products	No interests declared	
Filip Van Nuffel	Expert	BE - Federal Agency for Medicines and Health Products	No interests declared	
Peter Kiely	Expert	Ireland - HPRA	No interests declared	
Nuala Kelly	Expert	Ireland - HPRA	No interests declared	
Monique Wakelkamp	Expert	MPA.SE	No restrictions applicable to this meeting	
Graziella CURTALE	Expert	AIFA.IT	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Filomena Nappi	Expert	AIFA.IT	No interests declared	
Giuseppe Pimpinella	Expert	AIFA.IT	No interests declared	
Karin Janssen van Doorn	Expert	BE - Federal Agency for Medicines and Health Products	No interests declared	
Armando Genazzani	Expert	AIFA.IT	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.